

CIRSE 23 – HDT SESSIONS ON EMBOLISATION





DEMONSTRATION ON COMPATIBILITY & DRUG ELUTION PROFILE

- **BSC mCath Family Compatibility**
 - ✓ Size Distribution Consistency No aggregation in cath
 - ✓ Compresibility and Re-gain shape
- **☐** Drug Elution Profile
 - ✓ Both DC Bead™ and DC Bead LUMI™ demonstrate controlled and prolonged release profiles
- Radiopacity of LUMI™
 - ✓ Persistent visibility of LUMI at 6 week follow-up
 - Marking to guide future interventions





Embosphere® & EmboGold®

Microspheres



Microspheres

Class 2B, Trisacryl, 7 sizes

- Over 250 clinical articles
- Predictable
- Fast and stable endpoint
- Inert, low inflammatory profile
- Most published spherical embolic in UFE & PAE

Class 3A, copolymer

- Indicated for use with Doxo & Iri in TACE
- 1 vial / procedure
- Conformable optimal Embo & Drug delivery
- High Objective Tumour Response
- Reduced pain & complications
- Over 50 publications
- 15 days stability (loaded)



Embolisation Gelatin

- First gelatin foam indicated for intra-arterial use
- Can be delivered through catheters and microcatheters
- Slurry/Cube injection: The choice is yours!





HepaSphere^{**}

Drug Eluting Microspheres





EmboCept®S DSM 50 µm

DSM - Degradable Starch Microsphere

Substance: Amilomer (starch)

Half-life: 35 minutes (completely dissolved in 2 h)

Size: 50 μ m diameter (range: 20-90 μ m) Enzymatic degradation by α -amylase

Indication:

intra-arterial treatment of inoperable liver tumours and lung tumours in combination with cytostatic agents, TACE







SIR-Spheres® Y-90 resin microspheres



Optimized Activity

Delivery vials with multiple activities available five days a week give you various options, every day.



Maximized Coverage

44 ± 2.6 million microspheres available, providing confidence in coverage.*



Precise Dosimetry

Drawing up customized dose enables personalized and precise patient treatment.

TERUMO PARTICULATE AGENTS PORTFOLIO



- Loadable with 4 chemotherapeutic drugs Doxorubicin, Idarubicin, Epirubicin and Irinotecan
- ◆ Veloso et al published new standard in DEM-TACE overall survival with a 580 unresectable HCC patients cohort analysis with a median overall survival of 50.8 months¹.



- Occlude blood vessels for therapeutic purposes including in
 - Benign prostatic hyperplasia
 - Uterine fibroids
 - Bleeding and trauma and preoperative reduction of bleeding
 - Hypervascularised tumors

QuiremSpheres Holmium-166 Microspheres

QuiremScout[®]

Holmium-166 Microspheres

Q-Suite

Imaging Software

- ◆ The Holmium Platform: Three integrated products delivering individualized SIRT at its' full potential
 - ◆ QuiremScout® is the first and only CEmarked SIRT work-up product that utilizes the same technology as the therapeutic microspheres which aims to optimize patient selection and advance treatment planning
 - ◆ QuiremSpheres® Holmium-166 SIRT microspheres for the treatment of liver cancer





Embozene and Embozene Tandem Microspheres

Precisely calibrated microspheres



